Irinotecan Kabi (Irinotecan Hydrochloride Trihydrate)

After administration, Irinotecan is metabolised to SN‑38, which inhibits topoisomerase I. This prevents the re‑ligation of single‑strand DNA breaks, leading to accumulation of DNA damage, interruption of replication and transcription, and ultimately tumour cell death.

The dose of Irinotecan Kabi is determined by the prescribing oncologist based on the patient’s body surface area, disease stage, prior therapies and organ function. No fixed regimen is provided here; the prescriber sets the appropriate dosing schedule.

Safety data for Irinotecan Kabi in pregnancy and lactation are limited. It is generally avoided unless the potential benefit justifies the potential risk to the fetus or infant. Women of child‑bearing potential should use effective contraception during treatment.

To place an order, submit an enquiry on the Irinotecan Kabi product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Irinotecan and topotecan are both topoisomerase I inhibitors, but Irinotecan is commonly used for colorectal and small cell lung cancers, whereas topotecan is approved mainly for ovarian and small cell lung cancers. Differences include dosing schedules, metabolic pathways (SN‑38 for Irinotecan) and specific toxicity profiles.

Irinotecan Kabi should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, light and physical shock. Reconstitute and use according to the supplied instructions, and discard any unused portion after the recommended time.

Irinotecan Kabi is given by intravenous infusion, usually over 30 to 90 minutes depending on the protocol. The infusion is performed in a clinical setting by qualified healthcare professionals, with appropriate monitoring for infusion‑related reactions.

The most serious adverse events include severe neutropenia or febrile neutropenia, life‑threatening diarrhoea or colitis, hepatic toxicity, and rare but severe allergic reactions. Prompt medical attention is required if patients develop fever, persistent diarrhoea, jaundice or signs of anaphylaxis.

Irinotecan Kabi is contraindicated in patients with known hypersensitivity to irinotecan or any excipients, those with severe bone‑marrow suppression, uncontrolled infections, or significant hepatic impairment that precludes dose adjustment. Clinicians should also avoid use in patients with recent bowel obstruction.